Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI
A. Koshy(The University of Melbourne), Roxana Mehran(Mount Sinai Hospital), Bimmer E. Claessen(Columbia University Irving Medical Center), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Annapoorna Kini(Mount Sinai Medical Center), Samin K. Sharma(Mount Sinai Health System), Anastasios Roumeliotis(Cardiovascular Institute of the South), Gennaro Giustino(Cardiovascular Institute of the South), Zaha Waseem(Cardiovascular Institute of the South), Shiv Bagga(Cardiovascular Institute of the South), Anton Camaj(Columbia University Irving Medical Center), Zhongjie Zhang(Shanxi Medical University), Johny Nicolas(Cardiovascular Institute of the South), Rashi Bedekar(Cardiovascular Institute of the South), Matthew A. Levin(Icahn School of Medicine at Mount Sinai), Rishi Chandiramani(Cardiovascular Institute of the South), Htoo Kyaw(Cardiovascular Institute of the South), Davide Cao(Cardiovascular Institute of the South)
Cited by 2
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k